authors
- Biziotis, Olga-Demetra
- Tsakiridis, Evangelia-Evelyn
- Broadfield, Lindsay
- Farrell, Thomas
- Menjolian, Gabe
- Mathurin, Tammy
- Mekhaeil, Bassem
- Zacharidis, Panagiotis
- Muti, Paola
- Abdulkarim, Bassam
- Steinberg, Gregory
- Tsakiridis, Theos
CANAGLIFLOZIN, A NEW ANTI-DIABETIC AGENT TARGETING CELLULAR METABOLISM, SUPPRESSES SURVIVAL AND ENHANCES THE RESPONSE OF NON-SMALL CELL LUNG CANCER (NSCLC) TO RADIOTHERAPY
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- October 1, 2019
has subject area
- 0299 Other Physical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Radiotherapy and Oncology Journal